Levodopa - CAS 59-92-7
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Dopamine Receptor
Levodopa (Sinemet) is an amino acid precursor of dopamine with antiparkinsonian properties.
Publictions citing BOC Sciences Products
  • >> More
1.Efficiency of the occlusion therapy with and without levodopa-carbidopa in amblyopic children-A tertiary care centre experience.
Sofi IA1, Gupta SK2, Bharti A3, Tantry TG4. Int J Health Sci (Qassim). 2016 Apr;10(2):249-57.
OBJECTIVES: To assess the role, efficacy and tolerability of levodopa-carbidopa in the management of small and older children with different types of amblyopia.
2.Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition.
Cossu G1, Ceravolo R2, Zibetti M3, Arca R4, Ricchi V4, Paribello A4, Murgia D4, Merola A3, Romagnolo A3, Nicoletti V2, Palermo G2, Mereu A5, Lopiano L3, Melis M4, Abbruzzese G6, Bonuccelli U2. Parkinsonism Relat Disord. 2016 Apr 20. pii: S1353-8020(16)30120-1. doi: 10.1016/j.parkreldis.2016.04.016. [Epub ahead of print]
OBJECTIVE: Our purpose was to determine whether the use of catechol-O-methyltransferase-inhibitors (ICOMT) can reduce the risk of developing levodopa (LD)-induced neuropathy in Parkinson's disease (PD) patients.
3.The single intake of levodopa modulates implicit learning in drug naïve, de novo patients with idiopathic Parkinson's disease.
Geffe S1, Schindlbeck KA1, Mehl A1, Jende J2, Klostermann F1, Marzinzik F3. J Neural Transm (Vienna). 2016 Apr 23. [Epub ahead of print]
Although dopamine is known to aggravate implicit learning, the exact impact on behaviour when feedback is unavailable remains unclear. Previous studies revealed that non-rewarded learning habits are affected in long-term dopaminergic treated patients with Parkinson's disease (PD). We studied the influence of a onetime levodopa intake on implicit learning in de novo, untreated PD patients. De novo PD patients (n = 22) before and after the single intake of levodopa and control subjects (n = 23) took part in a Go/NoGo paradigm. One stimulus was defined as target, which was first consistently preceded by one of three non-target stimuli (conditioning). This coupling was dissolved thereafter (deconditioning). In the 'Go version' subjects were asked to respond to the target by pressing a key, whereas in the 'NoGo version' response had to be inhibited. PD patients and controls (n = 14/n = 19) with an initial learning effect due to the target were included for further statistical analysis.
4.Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding.
Ivanova SA1, Loonen AJ2. Parkinsons Dis. 2016;2016:6461907. doi: 10.1155/2016/6461907. Epub 2016 Apr 6.
A serendipitous pharmacogenetic finding links the vulnerability to developing levodopa-induced dyskinesia to the age of onset of Huntington's disease. Huntington's disease is caused by a polyglutamate expansion of the protein huntingtin. Aberrant huntingtin is less capable of binding to a member of membrane-associated guanylate kinase family (MAGUKs): postsynaptic density- (PSD-) 95. This leaves more PSD-95 available to stabilize NR2B subunit carrying NMDA receptors in the synaptic membrane. This results in increased excitotoxicity for which particularly striatal medium spiny neurons from the indirect extrapyramidal pathway are sensitive. In Parkinson's disease the sensitivity for excitotoxicity is related to increased oxidative stress due to genetically determined abnormal metabolism of dopamine or related products. This probably also increases the sensitivity of medium spiny neurons for exogenous levodopa. Particularly the combination of increased oxidative stress due to aberrant dopamine metabolism, increased vulnerability to NMDA induced excitotoxicity, and the particular sensitivity of indirect pathway medium spiny neurons for this excitotoxicity may explain the observed increased prevalence of levodopa-induced dyskinesia.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Dopamine Receptor Products

CAS 66644-81-3 Veralipride

(CAS: 66644-81-3)

Veralipride is a D2 receptor antagonist in the hypothalamic system and has a half-life of approximately 12 hours. Veralipride is highly active on the neurotrans...

CAS 67227-57-0 Fenoldopam Mesylate

Fenoldopam Mesylate
(CAS: 67227-57-0)

Fenoldopam is a selective D1 receptor partial agonist, binds to α2-adrenoceptors, increasing renal blood flow used as an antihypertensive agent.

CAS 522-97-4 Tetrahydroberberine

(CAS: 522-97-4)

Tetrahydroberberine is a protoberberine alkaloid acts as a calcium channel blocker.

CAS 15676-16-1 Sulpiride

(CAS: 15676-16-1)

Sulpiride, a D2 receptor a antagonist, with antipsychotic adn antidepressant properties it can be used to treat used in schizophrenia or senile dementia etc., b...

CAS 179386-44-8 Sumanirole maleate

Sumanirole maleate
(CAS: 179386-44-8)

Sumanirole maleate, also referred as PNU 95666E or U95666E, is a high affinity D2 receptor full agonist that shows >200-fold selectivity over dopamine receptor ...

CAS 67227-56-9 Fenoldopam

(CAS: 67227-56-9)

Fenoldopam is a selective D1 receptor partial agonist, binds to α2-adrenoceptors, increasing renal blood flow used as an antihypertensive agent.

A 437203
(CAS: 220519-06-2)

A 437203 is a selective dopamine (DA) D3 receptor antagonist suited to evaluate the physiological role(s) of D3 receptors. A 437203 shows an approximately 100-f...

CAS 69-23-8 Fluphenazine

(CAS: 69-23-8)

Fluphenazine, sold under the brand names Prolixin

CAS 104632-28-2 Dexpramipexole

(CAS: 104632-28-2)

Dexpramipexole, also known as R-(+)-Pramipexole, is one of the impurities of pramipexole(USP D). It coule be used as a negative control in the research of dopam...

CAS 66104-23-2 Pergolide Mesylate

Pergolide Mesylate
(CAS: 66104-23-2)

Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist.

CAS 7416-34-4 Molindone

(CAS: 7416-34-4)

Molindone is dopamine D2 receptor antagonist which can be used in the treatment of schizophrenia. Molindone can block the effects of dopamine in the brain, lead...

(CAS: 108351-90-2)

PD-118440 is a dopamine antagonist. It was identified as orally active dopamine (DA) agonists with pronounced central nervous system effects in tests including ...

CAS 34161-24-5 Fipexide hydrochloride

Fipexide hydrochloride
(CAS: 34161-24-5)

Fipexide hydrochloride is a nootropic agent that displays a positive effect on cognitive function

(CAS: 195875-68-4)

NS-2359, a serotonin-norepinephrine-dopamine reuptake inhibitor, may be able to reduce cocaine withdrawal symptoms, reduce cocaine craving and reduce cocaine-in...

CAS 84226-12-0 Eticlopride

(CAS: 84226-12-0)

Eticlopride is a selective dopamine D2 antagonist . It was initially developed as a potential antipsychotic agent. Now Eticlopride is primarily used in pharmaco...

(CAS: 913611-97-9)

Brexpiprazole, a novel atypical antipsychotic drug, is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). It is approved for the...

(CAS: 82668-33-5)

JPC-211 is a selective dopamine D3 receptor agonist.

CAS 1420-55-9 thiethylperazine

(CAS: 1420-55-9)

Thiethylperazine is a dopamine receptor antagonist It is an antiemetic of the phenothiazine class. Though it was never licensed or used as an antipsychotic, it ...

Nolomirole hydrochloride
(CAS: 138531-51-8)

Nolomirole is a Alpha 2 adrenergic receptor and Dopamine D2 receptor agonist. Nolomirole can attenuate the heart failure signs in the monocrotaline-induced cong...

CAS 113-59-7 Chlorprothixene

(CAS: 113-59-7)

Chlorprothixene has strong binding affinities to dopamine and histamine receptors, such as D1, D2, D3, D5, H1, 5-HT2, 5-HT6 and 5-HT7, with Ki of 18 nM, 2.96 nM...

Chemical Structure

CAS 59-92-7 Levodopa

Quick Inquiry

Verification code

Featured Items